Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus

F Bani-Sadr; P Palmer; C Scieux; J M Molina

doi:10.1086/424012

Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus

Clin Infect Dis. 2004 Oct 1;39(7):1062-4. doi: 10.1086/424012. Epub 2004 Sep 13.

Authors

F Bani-Sadr¹, P Palmer, C Scieux, J M Molina

Affiliation

¹ Service des Maladies Infectieuses et Tropicales, Hôpital Saint Louis, Paris, France. firouze.bani-sadr@tnn.ap-hop-paris.fr

PMID: 15472862
DOI: 10.1086/424012

Abstract

We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir. The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection.

Publication types

Clinical Trial

MeSH terms

Adenine / analogs & derivatives*
Adenine / therapeutic use
Adult
Anti-HIV Agents / therapeutic use*
Drug Therapy, Combination
Female
HIV Infections / complications
HIV Infections / drug therapy*
Hepatitis B / complications
Hepatitis B / drug therapy*
Humans
Lamivudine / therapeutic use*
Male
Middle Aged
Organophosphonates / therapeutic use*
Tenofovir

Substances

Anti-HIV Agents
Organophosphonates
Lamivudine
Tenofovir
Adenine